Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Sanofi : may seek U.S. approval for Dengvaxia despite Philippines outrage

share with twitter share with LinkedIn share with facebook
share via e-mail
03/08/2018 | 05:58pm CET
FILE PHOTO:French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris

(This version of Mar.7's story corrects timeframe of filing decision in the United States in bullet point and paragraphs 10-11.)

PARIS (Reuters) - French pharmaceuticals group Sanofi says it will decide shortly whether to seek regulatory approval for dengue vaccine Dengvaxia in the United States, saying it was committed to the medicine despite a health scare in the Philippines.

David Loew, the head of Sanofi Pasteur, the group's vaccines division, said the company had complied with all regulations and had no regrets about the vaccine, Dengvaxia, was developed despite the Philippines suspending a vast government immunisation programme because of safety concerns.

"On the whole path of development, we always worked with the WHO and experts in the dengue community. We were always transparent," Loew told Reuters in an interview, referring to the World Health Organization and other regulators.

"You need to ask yourself: what was done with the information that was available at the time? Looking back, I would say no, we would not have done anything differently."

Loew said the company was contemplating the possibility of filing an application for the use of Dengvaxia in the United States and that a meeting with the Food and Drug Administration would take place within two months.

Any decision would be taken after the meeting, he said.

Some experts have argued Sanofi and regulators may have ignored warnings about how the vaccine was developed, but executives at Sanofi denied any errors.

Dengvaxia has been approved and registered in 19 countries, mostly in the developing world. It is currently under review by the European Medicines Agency.

(Reporting by Matthias Blamont; editing by Luke Baker)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
03/23SANOFI : House eyeing P1.2-billion vaccine refund for Dengvaxia kids
03/23SANOFI : Senate to recommend Dengvaxia raps vs Aquino, Abad, Garin
03/22SANOFI : Studies from Sanofi Update Current Data on Mucopolysaccharidoses (Fast,..
03/22SANOFI : Researchers from Sanofi Provide Details of New Studies and Findings in ..
03/22Drugmaker Novo Nordisk looks to former oil boss to energise M&A
03/22SANOFI : Gov`t wants Sanofi refund used to help Dengvaxia recipients
03/22SANOFI : Joins the Speaker Line-Up for SMi's Launch, Injectable Drug Delivery 20..
03/20SANOFI : Joins the Speaker Line-up for SMi's Launch, Injectable Drug Delivery 20..
03/16SANOFI : Mentorship Program Offers Guidance for Students
03/15SANOFI : DOH ignored warnings on Dengvaxia - expert
More news
News from SeekingAlpha
03/23Premarket analyst action - healthcare 
03/153 THINGS IN BIOTECH, MARCH 14 : Alnylam Breaks Through, Merck A Go In Cervical? .. 
03/15Sanofi prices ?8B bond issues 
03/13SPECIALTY RESEARCH : Stellar Gene Therapy And Gene Editing Innovators 
03/13YOUR DAILY PHARMA SCOOP : Coherus Biosciences Surges, Savara's Aironite Flops, B.. 
Financials (€)
Sales 2018 35 243 M
EBIT 2018 8 765 M
Net income 2018 5 232 M
Debt 2018 13 190 M
Yield 2018 4,81%
P/E ratio 2018 14,98
P/E ratio 2019 13,67
EV / Sales 2018 2,64x
EV / Sales 2019 2,50x
Capitalization 79 894 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,8 €
Spread / Average Target 25%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.33%98 688
JOHNSON & JOHNSON-8.83%335 598
NOVARTIS-7.31%207 583
PFIZER0.14%205 314
ROCHE HOLDING LTD.-12.37%196 669
MERCK AND COMPANY-5.08%144 004